Evamist.com

Simple spray application that women find easy to use

In an experience study, women ranked Evamist 8.3 out of 9 for ease-of-use, with 9 being very easy to use^*1
In the same study, convenience was the #1 Evamist attribute women found important^†1

3 out of 4 women reported that Evamist spray was more convenient than their previous patch therapy^‡1

Fits easily into her daily routine

Once-daily application with 1, 2, or 3 sprays to a small area of the inner forearm²
Dries quickly so patients can apply and go^§1
No need to touch medication or wash hands following application²

Evamist offers the flexibility of dosing adjustments when needed

Flexible titration with three dosing options in one applicator²
No need to issue a new prescription initially for dosing adjustments²

» References

As reported in an experience study of 247 women using Evamist.¹

†

In an experience study of 247 women using Evamist, the majority of women ranked convenience higher in importance than any other Evamist attribute.¹

‡

As reported in an experience study of 247 women using Evamist, 53 of whom had previously used estrogen patch therapy.¹

Dries in a median of 67 seconds. Patients should let spray dry for at least 2 minutes before dressing, and at least 30 minutes before washing.^1,2

Important Safety Information

Indication
Evamist^® is indicated for the treatment of moderate-to-severe vasomotor symptoms due to menopause.

WARNING—ENDOMETRIAL CANCER, CARDIOVASCULAR, AND OTHER RISKS

ENDOMETRIAL CANCER Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding.

CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 6.8 years and 7.1 years, respectively, of treatment with daily oral conjugated estrogens (CE 0.625 mg), relative to placebo. The estrogen plus progestin WHI substudy reported increased risk of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and DVT in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE 0.625 mg combined with medroxyprogesterone acetate (MPA 2.5 mg), relative to placebo. The Women’s Health Initiative Memory Study (WHIMS), a substudy of the WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE 0.625 mg alone and during 4 years of treatment with daily CE 0.625 mg combined with MPA 2.5 mg, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women. In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA and other combinations and dosage forms of estrogens and progestins. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

Evamist should not be used in women with undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active deep vein thrombosis, pulmonary embolism, or history of these conditions; active or recent arterial thromboembolic disease; liver dysfunction or disease; or known or suspected pregnancy.

In a clinical trial with Evamist, the most common side effects were headache, breast tenderness, nasopharyngitis, nipple pain, back pain, nausea, and arthralgia.

Please see full prescribing information for Evamist, including boxed warnings.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.